Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases February 26, 2026
Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program February 26, 2026
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics February 26, 2026
Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity February 6, 2026
